Longevity of daily oral Vitamin D3 supplementation: differences in 25OHD and 24,25(OH)2D observed 2 years after cessation of a 1-year randomized controlled trial (VICtORy RECALL)

H. M. MacDonald (Corresponding Author), A. Gryka, J. C. Y. Tang, L. S. Aucott, W. D. Fraser, A. D. Wood

Research output: Contribution to journalArticle

2 Citations (Scopus)
7 Downloads (Pure)

Abstract

Purpose: To determine longevity of vitamin D status following cessation of vitamin D3 supplementation, 2 and 3 years after a 1-year randomised, double-blind placebo controlled trial; and to investigate possible predictive factors. Method: Caucasian non-smoking postmenopausal women randomised to ViCtORY (2009-2010), who had not taken vitamin D supplements since the trial ended, were invited to attend follow up visits. Total 25-hydroxyvitamin D (25OHD) and 24,25-dihydroxyvitamin D (24,25OH2D) were measured by dual tandem mass spectrometry of serum samples following removal of protein and de-lipidation; the original RCT samples were reanalysedsimultaneously. Vitamin D binding protein (VDBP) was measured by monoclonal immunoassay. Results: In March 2012 and March 2013, 159 women (mean (SD) age 67.6 (2.1) years) reattended, equally distributed between the original treatment groups: daily vitamin D3 400IU; 1000IU; and placebo. One month after the RCT ended (March 2010) the proportion of women in placebo, 400IU, and 1000IU vitamin D3 groups, respectively, with 25OHD<25 nmol/ L was 15%,0%, 0% (Chi-square p<0.001, n=46,44,54). After 2 years (March 2012) it was 22%, 4%, 4% (p=0.002, n=50,48,57); after 3 years 23%, 13%, 15% (p=0.429,n=48,45,52). The respective proportions of women with 24,25OH2D < 2.2nmol/L were 50%, 2%, 2% (1 month, p>0.001, n=46,44,54); 42%, 33%, 12% (2y, p=0.002,n=50,48,57) and 45%, 27%, 29% (3y, p=0.138, n=47,45,51,). VDBP was a predictor of circulating 25OHD longevity (beta for VDBP in µg/ml:0.736; 95% CI 0.216-1.255,p=0.006) but not 24,25OH2D. Conclusion: 400 IU (or 1000 IU) daily vitamin D3 showed benefits over placebo 2 years after supplementation ceased, in keeping 25OHD >25 nmol/L.
Original languageEnglish
Pages (from-to)3361-3372
Number of pages12
JournalOsteoporosis International
Volume28
Issue number12
Early online date15 Sep 2017
DOIs
Publication statusPublished - Dec 2017

Fingerprint

Cholecalciferol
Vitamin D-Binding Protein
Randomized Controlled Trials
Placebos
Vitamin D
Dihydroxycholecalciferols
Tandem Mass Spectrometry
Immunoassay
Serum
Proteins
Therapeutics

Keywords

  • Daily vitamin D
  • 25-hydroxyvitamin D
  • 24,25-dihydroxy vitamin D
  • RCT
  • longevity
  • postmenopausal women

Cite this

@article{95532e60838d438ab9578bd48908df6b,
title = "Longevity of daily oral Vitamin D3 supplementation: differences in 25OHD and 24,25(OH)2D observed 2 years after cessation of a 1-year randomized controlled trial (VICtORy RECALL)",
abstract = "Purpose: To determine longevity of vitamin D status following cessation of vitamin D3 supplementation, 2 and 3 years after a 1-year randomised, double-blind placebo controlled trial; and to investigate possible predictive factors. Method: Caucasian non-smoking postmenopausal women randomised to ViCtORY (2009-2010), who had not taken vitamin D supplements since the trial ended, were invited to attend follow up visits. Total 25-hydroxyvitamin D (25OHD) and 24,25-dihydroxyvitamin D (24,25OH2D) were measured by dual tandem mass spectrometry of serum samples following removal of protein and de-lipidation; the original RCT samples were reanalysedsimultaneously. Vitamin D binding protein (VDBP) was measured by monoclonal immunoassay. Results: In March 2012 and March 2013, 159 women (mean (SD) age 67.6 (2.1) years) reattended, equally distributed between the original treatment groups: daily vitamin D3 400IU; 1000IU; and placebo. One month after the RCT ended (March 2010) the proportion of women in placebo, 400IU, and 1000IU vitamin D3 groups, respectively, with 25OHD<25 nmol/ L was 15{\%},0{\%}, 0{\%} (Chi-square p<0.001, n=46,44,54). After 2 years (March 2012) it was 22{\%}, 4{\%}, 4{\%} (p=0.002, n=50,48,57); after 3 years 23{\%}, 13{\%}, 15{\%} (p=0.429,n=48,45,52). The respective proportions of women with 24,25OH2D < 2.2nmol/L were 50{\%}, 2{\%}, 2{\%} (1 month, p>0.001, n=46,44,54); 42{\%}, 33{\%}, 12{\%} (2y, p=0.002,n=50,48,57) and 45{\%}, 27{\%}, 29{\%} (3y, p=0.138, n=47,45,51,). VDBP was a predictor of circulating 25OHD longevity (beta for VDBP in µg/ml:0.736; 95{\%} CI 0.216-1.255,p=0.006) but not 24,25OH2D. Conclusion: 400 IU (or 1000 IU) daily vitamin D3 showed benefits over placebo 2 years after supplementation ceased, in keeping 25OHD >25 nmol/L.",
keywords = "Daily vitamin D, 25-hydroxyvitamin D, 24,25-dihydroxy vitamin D, RCT, longevity, postmenopausal women",
author = "MacDonald, {H. M.} and A. Gryka and Tang, {J. C. Y.} and Aucott, {L. S.} and Fraser, {W. D.} and Wood, {A. D.}",
note = "This work was funded partly by the UK Food Standards Agency, and the Department of Health . Any views expressed are the authors own. Original trial registration: Vitamin D effects on cardiovascular disease risk (VICtORy) study at controlled̺trials.com as ISRCTN20328039 (http://controlled̺trials.com/ISRCTN20328039/). We wish to thank all the women volunteers taking part in this study; Karen Secombes, Minimol Paulose and Jenny Scott for assistance with venesection; Martin Allen, Health Protection Agency, Cambridge for help in standardising the UVA badges; Maciej Gryka for creating the algorithms used to extract the data from the UVA badges; and Hamish Macdonald for assistance in generating the figures.",
year = "2017",
month = "12",
doi = "10.1007/s00198-017-4201-2",
language = "English",
volume = "28",
pages = "3361--3372",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "SPRINGER-VERLAG LONDON LTD",
number = "12",

}

TY - JOUR

T1 - Longevity of daily oral Vitamin D3 supplementation

T2 - differences in 25OHD and 24,25(OH)2D observed 2 years after cessation of a 1-year randomized controlled trial (VICtORy RECALL)

AU - MacDonald, H. M.

AU - Gryka, A.

AU - Tang, J. C. Y.

AU - Aucott, L. S.

AU - Fraser, W. D.

AU - Wood, A. D.

N1 - This work was funded partly by the UK Food Standards Agency, and the Department of Health . Any views expressed are the authors own. Original trial registration: Vitamin D effects on cardiovascular disease risk (VICtORy) study at controlled̺trials.com as ISRCTN20328039 (http://controlled̺trials.com/ISRCTN20328039/). We wish to thank all the women volunteers taking part in this study; Karen Secombes, Minimol Paulose and Jenny Scott for assistance with venesection; Martin Allen, Health Protection Agency, Cambridge for help in standardising the UVA badges; Maciej Gryka for creating the algorithms used to extract the data from the UVA badges; and Hamish Macdonald for assistance in generating the figures.

PY - 2017/12

Y1 - 2017/12

N2 - Purpose: To determine longevity of vitamin D status following cessation of vitamin D3 supplementation, 2 and 3 years after a 1-year randomised, double-blind placebo controlled trial; and to investigate possible predictive factors. Method: Caucasian non-smoking postmenopausal women randomised to ViCtORY (2009-2010), who had not taken vitamin D supplements since the trial ended, were invited to attend follow up visits. Total 25-hydroxyvitamin D (25OHD) and 24,25-dihydroxyvitamin D (24,25OH2D) were measured by dual tandem mass spectrometry of serum samples following removal of protein and de-lipidation; the original RCT samples were reanalysedsimultaneously. Vitamin D binding protein (VDBP) was measured by monoclonal immunoassay. Results: In March 2012 and March 2013, 159 women (mean (SD) age 67.6 (2.1) years) reattended, equally distributed between the original treatment groups: daily vitamin D3 400IU; 1000IU; and placebo. One month after the RCT ended (March 2010) the proportion of women in placebo, 400IU, and 1000IU vitamin D3 groups, respectively, with 25OHD<25 nmol/ L was 15%,0%, 0% (Chi-square p<0.001, n=46,44,54). After 2 years (March 2012) it was 22%, 4%, 4% (p=0.002, n=50,48,57); after 3 years 23%, 13%, 15% (p=0.429,n=48,45,52). The respective proportions of women with 24,25OH2D < 2.2nmol/L were 50%, 2%, 2% (1 month, p>0.001, n=46,44,54); 42%, 33%, 12% (2y, p=0.002,n=50,48,57) and 45%, 27%, 29% (3y, p=0.138, n=47,45,51,). VDBP was a predictor of circulating 25OHD longevity (beta for VDBP in µg/ml:0.736; 95% CI 0.216-1.255,p=0.006) but not 24,25OH2D. Conclusion: 400 IU (or 1000 IU) daily vitamin D3 showed benefits over placebo 2 years after supplementation ceased, in keeping 25OHD >25 nmol/L.

AB - Purpose: To determine longevity of vitamin D status following cessation of vitamin D3 supplementation, 2 and 3 years after a 1-year randomised, double-blind placebo controlled trial; and to investigate possible predictive factors. Method: Caucasian non-smoking postmenopausal women randomised to ViCtORY (2009-2010), who had not taken vitamin D supplements since the trial ended, were invited to attend follow up visits. Total 25-hydroxyvitamin D (25OHD) and 24,25-dihydroxyvitamin D (24,25OH2D) were measured by dual tandem mass spectrometry of serum samples following removal of protein and de-lipidation; the original RCT samples were reanalysedsimultaneously. Vitamin D binding protein (VDBP) was measured by monoclonal immunoassay. Results: In March 2012 and March 2013, 159 women (mean (SD) age 67.6 (2.1) years) reattended, equally distributed between the original treatment groups: daily vitamin D3 400IU; 1000IU; and placebo. One month after the RCT ended (March 2010) the proportion of women in placebo, 400IU, and 1000IU vitamin D3 groups, respectively, with 25OHD<25 nmol/ L was 15%,0%, 0% (Chi-square p<0.001, n=46,44,54). After 2 years (March 2012) it was 22%, 4%, 4% (p=0.002, n=50,48,57); after 3 years 23%, 13%, 15% (p=0.429,n=48,45,52). The respective proportions of women with 24,25OH2D < 2.2nmol/L were 50%, 2%, 2% (1 month, p>0.001, n=46,44,54); 42%, 33%, 12% (2y, p=0.002,n=50,48,57) and 45%, 27%, 29% (3y, p=0.138, n=47,45,51,). VDBP was a predictor of circulating 25OHD longevity (beta for VDBP in µg/ml:0.736; 95% CI 0.216-1.255,p=0.006) but not 24,25OH2D. Conclusion: 400 IU (or 1000 IU) daily vitamin D3 showed benefits over placebo 2 years after supplementation ceased, in keeping 25OHD >25 nmol/L.

KW - Daily vitamin D

KW - 25-hydroxyvitamin D

KW - 24,25-dihydroxy vitamin D

KW - RCT

KW - longevity

KW - postmenopausal women

U2 - 10.1007/s00198-017-4201-2

DO - 10.1007/s00198-017-4201-2

M3 - Article

VL - 28

SP - 3361

EP - 3372

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 12

ER -